| Tirzepatide reduces body weight and improves glycemic control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health (Journal of Clinical Endocrinology & Metabolism)
In November 2021, we reviewed the evidence on SGLT2 inhibitors for adults with type 2 diabetes and chronic kidney disease, and made new recommendations (NICE)
Consultation documents (NICE)
Consultation documents (NICE)
Consultation documents (NICE)
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD (NICE)
Type 2 diabetes in adults – everything NICE says in an interactive flowchart (NICE)
Type 1 diabetes in adults – everything NICE says in an interactive flowchart (NICE)
The use of SGLT2i was associated with higher hemoglobin levels and lower prevalence of anemia in real clinical practice (Journal of Diabetes Investigation)
We demonstrate for the first time that metatranscriptomic activity of the gut microbiome is correlated with PPGR among adults (Diabetes Therapy)
| 
